TFX Stock - Teleflex Incorporated
Unlock GoAI Insights for TFX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.05B | $2.97B | $2.79B | $2.81B | $2.54B |
| Gross Profit | $1.70B | $1.65B | $1.53B | $1.55B | $1.32B |
| Gross Margin | 55.9% | 55.4% | 54.9% | 55.2% | 52.2% |
| Operating Income | $151.01M | $506.31M | $499.73M | $628.10M | $423.07M |
| Net Income | $69.67M | $356.33M | $363.14M | $485.37M | $335.32M |
| Net Margin | 2.3% | 12.0% | 13.0% | 17.3% | 13.2% |
| EPS | $1.49 | $7.58 | $7.74 | $10.38 | $7.21 |
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 4th 2025 | BofA Securities | Downgrade | Underperform | $140← $235 |
| February 28th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $155← $220 |
| February 28th 2025 | Raymond James | Downgrade | Market Perform | - |
| February 28th 2025 | Piper Sandler | Downgrade | Neutral | $140← $255 |
| February 27th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| July 1st 2024 | Piper Sandler | Upgrade | Overweight | $245← $205 |
| December 4th 2023 | Morgan Stanley | Upgrade | Overweight | $261 |
| June 21st 2023 | Needham | Downgrade | Hold | - |
| May 30th 2023 | CL King | Initiation | Buy | $293 |
| May 30th 2023 | Morgan Stanley | Resumed | Equal Weight | $261 |
| April 26th 2023 | Wolfe Research | Downgrade | Peer Perform | - |
| October 26th 2022 | Mizuho | Initiation | Neutral | $220 |
| October 14th 2022 | Stephens | Resumed | Overweight | $305 |
| October 12th 2022 | Jefferies | Initiation | Hold | $210 |
| July 29th 2022 | Wells Fargo | Downgrade | Equal Weight | $248 |
Earnings History & Surprises
TFXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $3.84 | — | — | — |
Q4 2025 | Nov 6, 2025 | $3.38 | $3.67 | +8.6% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $3.36 | $3.73 | +11.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $2.88 | $2.91 | +1.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $3.86 | $3.89 | +0.8% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $3.38 | $3.49 | +3.3% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $3.33 | $3.42 | +2.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $3.07 | $3.21 | +4.6% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $3.26 | $3.38 | +3.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $3.27 | $3.64 | +11.3% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $3.21 | $3.41 | +6.2% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $2.97 | $3.09 | +4.0% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $3.44 | $3.52 | +2.3% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $3.10 | $3.27 | +5.5% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $3.35 | $3.39 | +1.2% | ✓ BEAT |
Q2 2022 | Apr 28, 2022 | $2.73 | $2.88 | +5.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $3.53 | $3.60 | +2.0% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $3.03 | $3.51 | +15.8% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $2.86 | $3.35 | +17.1% | ✓ BEAT |
Latest News
Truist Securities Maintains Hold on Teleflex, Raises Price Target to $135
➖ NeutralWells Fargo Maintains Equal-Weight on Teleflex, Raises Price Target to $139
📈 PositiveTeleflex shares are trading higher after the company announced it will sell its Acute Care, Interventional Urology, and OEM businesses for $2.03 billion.
📈 PositiveTeleflex Board Of Directors Has Authorized A Share Repurchase Program For Up To $1B Of The Company's Common Stock
📈 PositiveMontagu And Kohlberg Agree To Acquire Teleflex Medical OEM From Teleflex For $1.5B In Carve-Out Transaction
📈 PositiveTeleflex Enters Agreement To Sell Acute Care, Interventional Urology And OEM Businesses For Combined $2.03B In Cash
📈 PositiveTruist Securities Maintains Hold on Teleflex, Lowers Price Target to $120
📉 NegativeRBC Capital Maintains Sector Perform on Teleflex, Lowers Price Target to $120
➖ NeutralWells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $114
📉 NegativeTeleflex Lowers FY2025 GAAP EPS Guidance from $6.73-$7.13 to $(4.42)-$(4.22).
📉 NegativeTeleflex Narrows FY2025 Adj EPS Guidance from $13.90-$14.30 to $14.00-$14.20 vs $14.03 Est; Narrows FY2025 Sales Guidance from $3.320B-$3.350B to $3.324B-$3.340B vs $3.331B Est
➖ NeutralTeleflex Q3 Adj. EPS $3.67 Beats $3.38 Estimate, Sales $913.021M Beat $892.777M Estimate
📈 PositiveTeleflex Enrolls First Patient In Dubstent Diabetes Trial Evaluating Dual-Device PCI Strategy Combining Drug-Coated Balloon And Drug-Eluting Stent With Optional Resorbable Magnesium Scaffold
📈 PositiveFrequently Asked Questions about TFX
What is TFX's current stock price?
What is the analyst price target for TFX?
What sector is Teleflex Incorporated in?
What is TFX's market cap?
Does TFX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TFX for comparison